| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 02/28/2008 | US20080050380 Glycoprotein VI and uses thereof |
| 02/28/2008 | US20080050376 Compositions And Uses Thereof For Identifying And Targeting Provasopressin-Expressing Cancer Cells |
| 02/28/2008 | US20080050372 Inhibition of alpha-2 hs glycoprotein (ahsg/fetuin) in obesity and insulin control of glucose homeostasis |
| 02/28/2008 | US20080050369 Therapeutic applications of T-BAM (CD40L) technology to treat diseases involving smooth muscle cells |
| 02/28/2008 | US20080050368 Humanized immunoglobulin reactive with B7 molecules and methods of treatment therewith |
| 02/28/2008 | US20080050363 Novel nucleic acid molecules encoding opioid growth factor receptors |
| 02/28/2008 | US20080050362 Methods of Inhibiting Tumor Cell Aggressiveness Using The Microenvironment of Human Embryonic Stem Cells |
| 02/28/2008 | US20080050361 Staphylococcus aureas specific anti-infectives |
| 02/28/2008 | US20080050358 Identification of Snps Associated with Hyperlipidemia, Dyslipidemia and Defective Carbohydrate Metabolism |
| 02/28/2008 | US20080050356 Liquefying a vitreous and/or inducing posterior vitreous detachment of an eye via microplasmin injection; treating vision defects; preventing or reducing the risk of retinal detachment |
| 02/28/2008 | US20080050352 Pharmaceutical Composition Comprising Botulinum, a Non Ionic Surfactant, Sodium Chloride and Sucrose |
| 02/28/2008 | US20080050351 Gene Therapy Approaches to Supply Apolipoprotein A-I Agonists and Their Use to Treat Dyslipidemic Disorder |
| 02/28/2008 | US20080050349 Cell based therapy for the pulmonary system |
| 02/28/2008 | US20080050342 Genetic inhibition by double-stranded RNA |
| 02/28/2008 | US20080050340 Cd40 agonist antibody /type 1 interferon synergistic adjuvant combination, conjugates containing and use thereof as a therapeutic to enhance cellular immunity |
| 02/28/2008 | US20080050339 Stable liquid interferon formulations |
| 02/28/2008 | US20080050338 Stable liquid interferon formulations |
| 02/28/2008 | US20080050337 Method for using calcium-sensitive potassium channel agonist for delivering a medicant to an abnormal brain region and/or a malignant tumor |
| 02/28/2008 | US20080050336 Hepatitis C Virus Inhibitors |
| 02/28/2008 | US20080050332 Method of skin care and/or treatment using glutaredoxin |
| 02/28/2008 | US20080050318 Use of a combination of components with an inhibitory synergistic effect on calcium channels to prevent or treat wrinkles and fine lines |
| 02/28/2008 | US20080050315 Diagnostics and Therapeutics for Diseases Associated with Protein Kinase, Cgmp-Dependent, Type I (Prkg1) |
| 02/28/2008 | US20080048052 Spray Nozzle Apparatus and Method of Use |
| 02/28/2008 | US20080047551 System for obfuscating identity |
| 02/28/2008 | DE602004007105T2 Zusammensetzung zur behandlung von gastrointestinalen störungen Composition for the treatment of gastrointestinal disorders |
| 02/28/2008 | DE19955576B4 Transferverbindungen, ihre Herstellung und ihre Verwendung Transfer compounds, their preparation and their use |
| 02/28/2008 | DE112004002364B4 Berechnung von Vertrauensniveaus zur Peptid- und Proteinidentifikation Calculation of confidence levels for peptide and protein identification |
| 02/28/2008 | CA2662862A1 Treatment of aplastic anemia |
| 02/28/2008 | CA2661924A1 Treatment of graft-versus-host disease |
| 02/28/2008 | CA2661814A1 Recombinant hcv e2 glycoprotein |
| 02/28/2008 | CA2661486A1 Cationic latex as a carrier for bioactive ingredients and methods for making and using the same |
| 02/28/2008 | CA2661430A1 Long-lasting absorption of flavonoids |
| 02/28/2008 | CA2661054A1 Prophylactic and/or therapeutic agents for peripheral neuropathy |
| 02/28/2008 | CA2660928A1 Methods and compositions for conserving and/or preparing an organ or tissue for transplant |
| 02/28/2008 | CA2660668A1 Small cationic antimicrobial peptides |
| 02/28/2008 | CA2658000A1 Use of cd83 in combination therapies |
| 02/27/2008 | EP1892299A2 Sense mRNA therapy |
| 02/27/2008 | EP1892298A1 Streptococcal C5a peptidase vaccine |
| 02/27/2008 | EP1892297A2 Identification and molecular characterisation of proteins, expressed in the tick salivary glands |
| 02/27/2008 | EP1892296A1 Generation and selection of recombinant varied binding proteins |
| 02/27/2008 | EP1892292A2 Recombinant bacterial phytases and uses thereof |
| 02/27/2008 | EP1892251A2 B7-related nucleic acids and polypeptides and their uses for immunomodulation |
| 02/27/2008 | EP1892250A2 CYR61 compositions and methods |
| 02/27/2008 | EP1892247A1 Dermopharmaceutical or cosmetic composition comprising enkephalin-derived peptides for reducing and/or eliminating facial wrinkles |
| 02/27/2008 | EP1892246A2 Antimicrobial peptides and method for identifying and using such peptides |
| 02/27/2008 | EP1891975A1 Anti-allergic complex molecules |
| 02/27/2008 | EP1891970A1 Beta glucan-based vaccines free of mannoprotein |
| 02/27/2008 | EP1891969A2 Novel anti-allergic agents |
| 02/27/2008 | EP1891967A1 Long-lasting absorption of flavonoids |
| 02/27/2008 | EP1891966A1 Modulation of activity of neurotrophins |
| 02/27/2008 | EP1891965A1 Hip-Kinase for fertility controll |
| 02/27/2008 | EP1891964A1 Application of initial doses of LHRH analogues and maintenance doses of LHRH antagonists for the treatment of hormone-dependent cancers and corresponding pharmaceutical kits |
| 02/27/2008 | EP1891963A1 Use of antagonists of PPY receptors for treating visceral pain or visceral hypersensitivity |
| 02/27/2008 | EP1891951A1 Viral polymerase inhibitors |
| 02/27/2008 | EP1891950A1 Viral polymerase inhibitors |
| 02/27/2008 | EP1891948A1 Treatment of neurological and neuropsychological disorders |
| 02/27/2008 | EP1891943A2 Nanoparticles comprising chitosan and cyclodextrin |
| 02/27/2008 | EP1891438A2 Methods for identifying ligands for stem cells and cells derived therefrom |
| 02/27/2008 | EP1891107A2 Compositions and methods for modulating immune responses |
| 02/27/2008 | EP1891105A2 Oxyntomodulin analogues and their effects on feeding behaviour |
| 02/27/2008 | EP1891100A2 Sclerostin epitopes |
| 02/27/2008 | EP1891099A1 Heterodimeric peptide compounds displaying ngf activity and their use to treat neurodegenerative disorders |
| 02/27/2008 | EP1891094A2 Scytovirin domain 1 related polypeptides |
| 02/27/2008 | EP1891093A1 Method of treating or preventing benign prostatic hyperplasia using modified pore-forming proteins |
| 02/27/2008 | EP1891090A2 Macrocyclic ghrelin receptor antagonists and inverse agonists and methods of using the same |
| 02/27/2008 | EP1891089A2 Hcv protease inhibitors in combination with food |
| 02/27/2008 | EP1890723A2 Stabilised il-21 compositions |
| 02/27/2008 | EP1890722A2 Methods of and compositions for stimulation of glucose uptake into muscle cells and treatment of diseases |
| 02/27/2008 | EP1890721A2 Compositions and methods for treating cardiac conditions |
| 02/27/2008 | EP1890720A2 Pharmaceutical compositions comprising casein derived peptides and methods of use thereof |
| 02/27/2008 | EP1890719A1 Topical oligopeptide delivery system |
| 02/27/2008 | EP1890718A2 Methods and compositions related to heightened apobec-1 related protein (arp) expression |
| 02/27/2008 | EP1890717A1 Nutrition formulations and methods of providing nutrition formulations |
| 02/27/2008 | EP1890716A2 Methods for the treatment of renal failure |
| 02/27/2008 | EP1890715A2 Peptides and peptide mimetics to treat pathologies characterized by an inflammatory response |
| 02/27/2008 | EP1890714A2 Treatment of autoimmune disorders with a neurotoxin |
| 02/27/2008 | EP1890701A1 Composition for the treatment of multiple sclerosis |
| 02/27/2008 | EP1890677A2 Pharmaceutical compositions and use thereof |
| 02/27/2008 | EP1575485A4 Methods for lightening skin and hair |
| 02/27/2008 | EP1471143B1 Method and kit of judging the onset of rheumatoid arthritis |
| 02/27/2008 | EP1438393B1 Differentiation of whole bone marrow |
| 02/27/2008 | EP1406694B1 Electro-medical device for use with biologics |
| 02/27/2008 | EP1406649B1 Use of substances with oxytocin activity against climacteric disorders |
| 02/27/2008 | EP1344821B9 Novel aggrecanase |
| 02/27/2008 | EP1341811B1 Orally ingestible preparation of mistletoe lectins and method |
| 02/27/2008 | EP1329504B1 Nucleic acid of novel human kinesin-associated gene, protein encoded by the nucleic acid, peptide fragment thereof and anticancer agents comprising the nucleic acid and the like |
| 02/27/2008 | EP1323732B9 Beta-catenin nuclear localizing protein |
| 02/27/2008 | EP1282700B1 Neuronal serine-threonine protein kinase |
| 02/27/2008 | EP1261723B1 Hybrid expression of neisserial proteins |
| 02/27/2008 | EP1237872B1 Compounds and compositions for delivering active agents |
| 02/27/2008 | EP1102850B1 Regions of papilloma virus e1 helicase involved in e1 oligomerization |
| 02/27/2008 | EP0981549B9 Use of an inhibitor substance for the improvement of neuronal regeneration |
| 02/27/2008 | EP0739350B1 Ligand that binds fas antigen |
| 02/27/2008 | CN101133160A Bacterial vector |
| 02/27/2008 | CN101133156A Chinese hamster apoptosis-related genes |
| 02/27/2008 | CN101133082A Acylated GLP-1 compounds |
| 02/27/2008 | CN101133080A Proteins of natural origin and materials made therefrom |
| 02/27/2008 | CN101132812A Polymer-based compositions and conjuates of HIV entry inhibitors |
| 02/27/2008 | CN101132809A Methods for treating renal cell carcinoma |
| 02/27/2008 | CN101132802A Novel method of neuroprotection by pharmacological inhibition of AMP-activated protein kinase |